Saturday, July 11, 2026

Drug profile · INN

efinopegdutide

efinopegdutide is a glucagon-like peptide 1 receptor agonist.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — efinopegdutide
Class
Route
Patents
0
Programs
3
Data quality
0.70

Quick answer

efinopegdutide is a glucagon-like peptide 1 receptor agonist.

Key facts

INN efinopegdutide
Mechanism Glucagon-like peptide 1 receptor agonist
Target Glucagon receptor

Mechanism of action

Glucagon-like peptide 1 receptor agonist

Primary target: Glucagon receptor

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Efinopegdutide Phase 2 · Merck KGaA, Darmstadt · Non-alcoholic Fatty Liver Disease
  2. Efinopegdutide 20 mg/mL Phase 2 · Merck KGaA, Darmstadt · Nonalcoholic Fatty Liver Disease
  3. MK-6024-017 Phase 2 · MSD Merck Sharp · Metabolic Dysfunction-Associated Steatohepatitis

Related & competitor drugs

  1. glucagon Systemic hormonal preparations (H04)
  2. dasiglucagon hydrochloride Glucagon receptor agonist
  3. glucagon hydrochloride Glucagon receptor agonist
  4. dasiglucagon Systemic hormonal preparations (H04)

Frequently asked questions

What is efinopegdutide?

efinopegdutide is a glucagon-like peptide 1 receptor agonist.